CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Natural Shield has developed SULIPRO, an oral therapeutic aimed at treating non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis. This treatment, derived from soy compounds, has shown efficacy in clinical trials and aims to provide an affordable over-the-counter option.
Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver causing inflammation and eventually lead to permanent scarring (cirrhosis), which can seriously impair the liver’s ability to functions. NAFLD can progress to non-alcoholic steatohepatitis (NASH), and then to liver failure resulting in death unless there is a liver transplant.
The prevalence of NAFLD in Europe is estimated to be between 26 and 33% of the general population.
Currently, there is no availab…
NATURAL SHIELD ISRAEL 2016 LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
